Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study

BMC Gastroenterology

Robert J de Knegt³  Solko W Schalm³  Avidan U Neumann¹  Jean-Michel Pawlotsky⁶  Carlo Ferrari^1,10  Stefan Zeuzem⁷  Francesco Negro⁹  Martin Lagging⁸  Juan I Esteban⁵  Yoav Lurie²  Bettina E Hansen³  Elke Verheij-Hart³  Arthur R Van Gool⁴  Geert Bezemer³ 

[1] Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel;Dpt. Gastroenterology, Sourasky Medical Center, Tel-Aviv, Israel;Dpt. Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands;Yulius Academy, Yulius, Organization for Mental Health, Rotterdam, the Netherlands;Dpt. Internal Medicine-Hepatology, Hospital General Vall d'Hebron, Barcelona, Spain;Dpt. Virology, Hopital Henri Mondor - Université Paris XII, Creteil, France;Dpt. Gastroenterology & Hepatology, Johann Wolfgang Goethe Hospital, Frankfurt, Germany;Dpt. Infectious Diseases, University of Gothenburg, Gothenborg, Sweden;Dpt. Gastroenterology & Hepatology, Hospital University of Genève, Genève, Switzerland;Dpt. Infectious Diseases and Hepatology, Azienda Ospedaliera di Parma, Parma, Italy

关键词: peginterferon;    hepatitis C;    health related quality of life;   

Others  :  1113144
DOI  :  10.1186/1471-230X-12-11

 received in 2011-07-28, accepted in 2012-01-31,  发布年份 2012

【 摘 要 】

Background

Hepatitis C decreases health related quality of life (HRQL) which is further diminished by antiviral therapy. HRQL improves after successful treatment. This trial explores the course of and factors associated with HRQL in patients given individualized or standard treatment based on early treatment response (Ditto-study).

Methods

The Short Form (SF)-36 Health Survey was administered at baseline (n = 192) and 24 weeks after the end of therapy (n = 128).

Results

At baseline HRQL was influenced by age, participating center, severity of liver disease and income. Exploring the course of HRQL (scores at follow up minus baseline), only the dimension general health increased. In this dimension patients with a relapse or sustained response differed from non-responders. Men and women differed in the dimension bodily pain. Treatment schedule did not influence the course of HRQL.

Conclusions

Main determinants of HRQL were severity of liver disease, age, gender, participating center and response to treatment. Our results do not exclude a more profound negative impact of individualized treatment compared to standard, possibly caused by higher doses and extended treatment duration in the individualized group. Antiviral therapy might have a more intense and more prolonged negative impact on females.

【 授权许可】

   
2012 Bezemer et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Foster GR, Goldin RD, Thomas HC: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998, 27:209-212.
• [2]Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F: Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005, 41:790-800.
• [3]Castera L, Constant A, Bernard PH, de Ledinghen V, Couzigou P: Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases. World J Gastroenterol 2006, 12:1545-1550.
• [4]Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N: The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999, 30:1299-1301.
• [5]Niederau C, Bemba G, Kautz A: [Socioeconomic characteristics, quality of life, and state of knowledge of patients with hepatitis C viral infection in Germany--socioeconomic aspects in hepatitis C]. Z Gastroenterol 2006, 44:305-317.
• [6]Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
• [7]Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, Ahl B, Manns MP, Boker KW: Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004, 41:845-851.
• [8]Bonkovsky HL, Woolley JM: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999, 29:264-270.
• [9]Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL: Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. In Hepatology. Volume 30. The Interventional Therapy Group; 1999::550-555.
• [10]McHutchison JG, Ware JE Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, Yang I, Neary MP, Hepatitis Interventional Therapy Group: The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001, 34:140-147.
• [11]Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, trejo-Estrada R, Horta E, Vale A, Wintfield N, green J: The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004, 40:675-681.
• [12]Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU, DITTO-HCV Study Group: International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005, 43:250-257.
• [13]Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A: Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995, 33(Suppl):AS264-79.
• [14]Wessely S, Pariante C: Fatigue, depression and chronic hepatitis C infection. Psychol Med 2002, 32:1-10.
• [15]Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM: Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007, 52:2531-2539.
• [16]Ware JE Jr, Kosinski M, Gandek B: SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute; 1993.
• [17]Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E: Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998, 51:1055-1068.
• [18]Lewin-Epstein N, Sagiv-Schifter T, Shabtai EL, Shmueli A: Validation of the 36-item short-form Health Survey (Hebrew version) in the adult population of Israel. Med Care 1998, 36:1361-1370.
• [19]Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R: Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004, 11:243-250.
• [20]Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH, PROACTIVE Study Group: Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004, 40:1450-1458.
• [21]Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group: Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007, 46:420-431.
• [22]Wagner AK, Gandek B, Aaronson NK, Acquadro C, Alonso J, Apolone G, Bullinger M, Bjorner J, Fukuhara S, Kaasa S, Leplege A, Sullivan M, Waud-Dauphinee S, Ware JE Jr: Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998, 51:925-932.
• [23]Bullinger M, Alonso J, Apolone G, Leplege A, Sullivan M, Wood-Dauphinee S, Gandek B, Wagner A, Aaronson N, Bech P, Fukuhara S, Kasa S, Ware JE Jr: Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol 1998, 51:913-923.